Prostate Cell News Volume 5.29 | Aug 8 2014

AKT/GSK-3β Regulates Stability and Transcription of Snail which Is Crucial for bFGF-Induced Epithelial-Mesenchymal Transition of Prostate Cancer Cells
Researchers demonstrate that basic fibroblast growth factor (bFGF) promoted epithelial-mesenchymal transition and motility of human prostate cancer PC-3 cells. [Biochim Biophys Acta] Abstract

Extracellular Iron Diminishes Anticancer Effects of Vitamin C: An In Vitro Study
Investigators show, using two prostate cancer cell lines (LNCaP and PC-3) and primary astrocytes, that the anticancer/cytotoxic effects of ascorbate are completely abolished by iron at physiological concentrations in cell culture medium and human plasma. [Sci Rep] Full Article

Establishment and Characterization of a Highly Tumorigenic African American Prostate Cancer Cell Line, E006AA-hT
Extensive characterization of the E006AA-hT cell line was accomplished using cytodifferentiation and prostate-specific markers, spectral karyotyping, cell line authentication assays, cell proliferation and migration assays, and in vitro tumorigenesis assays. [Int J Biol Sci] Full Article

Crosstalk between Nuclear MET and SOX9/β-Catenin Correlates with Castration Resistant Prostate Cancer
Scientists report the nuclear form of MET (nMET) is essential for castration resistant prostate cancer. Androgen-deprivation induces endogenous nMET and promotes cell proliferation and stem-like cell self-renewal in androgen non-responsive prostate cancer cells. [Mol Endocrinol] Abstract | Full Article

ORCA-010, A Novel Potency Enhanced Oncolytic Adenovirus, Exerts Strong Antitumor Activity in Preclinical Models
The results of in vitro cytotoxicity assays on 15 human cancer cell lines derived from different tumor types demonstrated that ORCA-010 is more potent than Ad5-Δ24RGD or ONYX-015. As ORCA-010 will initially be developed for the treatment of prostate cancer, selectivity experiments were performed using primary human prostate cells. [Hum Gene Ther] Abstract

Polymeric Nanoparticles for Targeted Radiosensitization of Prostate Cancer Cells
The nanoparticles were cytocompatible with immortalized prostate cells. Further, the particles showed a bi-phasic release of encapsulated 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one and were taken up by PC3 prostate cancer cells in a dose- and magnetic field-dependent manner while not being taken up in non-prostate cancer cell lines. [J Biomed Mater Res A] Abstract

The Role of Testicular Nuclear Receptor 4 in Chemo-Resistance of Docetaxel in Castration-Resistant Prostate Cancer
Scientists investigated the role of testicular nuclear receptor 4 (TR4) in docetaxel resistance in castration-resistant prostate cancer. Alternation of TR4 expression in prostate cancer cell line PC3 was applied to find out the influence of TR4 on half-maximal inhibitory concentration, cell viability and cell apoptosis. [Cancer Gene Ther] Abstract

CLINICAL RESEARCH

High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer
Investigators reviewed and analyzed the published data on high-dose-rate brachytherapy as monotherapy in the treatment of prostate cancer. [Brachytherapy] Abstract

Abiraterone Acetate and Prednisolone for Metastatic Castration-Resistant Prostate Cancer Failing Androgen Deprivation and Docetaxel-Based Chemotherapy: A Phase II Bridging Study in Korean and Taiwanese Patients
Investigators evaluated the safety and efficacy of abiraterone acetate and prednisolone in Korean and Taiwanese patients with metastatic castration-resistant prostate cancer not responding to docetaxel-based chemotherapy. [Int J Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

UAlbany Biologist Receives $1.43 Million NIH Award for Germline Research to Find Therapies for Cancer and Degenerative Diseases
University at Albany biologist Prashanth Rangan has received a $1.43 million grant from the National Institutes of Health (NIH) for his research into both preventing and inducing differentiation in stem cells in order to treat cancers and degenerative diseases. [University at Albany] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Senior Researcher – Interactions between Signaling Pathways of Cytokines, Growth Factors and Androgen Receptors (International Clinical Research Center – St. Anne’s University Hospital)

Postdoctoral Fellow – Cancer and miR Biology (Thomas Jefferson University Hospital)

PhD Position – Prostate Cancer Research (Institute of Oncology Research)

Postdoctoral Position – Cancer Biology/Genomics (Cornell University)

Postdoctoral Research Fellow – Mechanism of Gene Regulation in Prostate Cancer Development and Bone Metastasis (Brigham & Women’s Hospital – Harvard Medical School)

Associate Research Scientist – Molecular Mechanisms that Regulate Prostate Tumor Initiation and Formation of Cancer Stem Cells (Columbia University)

Postdoctoral Fellow – Computational Biology (Netherlands Cancer Institute)

Postdoctoral Fellow – Prostate Cancer Research (Institute of Oncology Research)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.